Form 4: Marimed COO Timothy Shaw Converts RSUs, Adjusts Holdings

Marimed's Chief Operating Officer, Timothy Shaw, reported the conversion of Restricted Stock Units into common stock and a subsequent tax-related share disposition.

Summary

• Timothy Shaw, Chief Operating Officer of Marimed Inc. (MRMD), reported transactions on September 7, 2025.
• Acquired 21,666 shares of common stock through the conversion of Restricted Stock Units (RSUs) at a price of $0.
• Disposed of 6,359 shares of common stock at $0.155 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, direct beneficial ownership stands at 8,990,590 shares.
• Indirectly owns 2,000,000 shares through the Shaw Family Trust, though beneficial ownership is disclaimed.
• The RSUs were granted on March 7, 2023, with remaining units set to vest on March 7, 2026.

Sentiment

Score: 6

Explanation: The filing reports a standard executive compensation event involving RSU vesting and a tax-related share disposition. While there's a net increase in direct shares from the RSU conversion, the disposition for taxes is a neutral, expected event. No significant positive or negative operational news is present.

Positives

• Conversion of Restricted Stock Units (RSUs) into common stock indicates a vesting event, which is a standard part of executive compensation.
• The acquisition of 21,666 shares increases direct ownership, even with the tax-related disposition.

Negatives

• Disposition of 6,359 shares, although for tax purposes, reduces the overall direct share count from the RSU conversion.

Future Outlook

Remaining Restricted Stock Units granted on March 7, 2023, are scheduled to vest on March 7, 2026, indicating future share issuances.

Management Comments

• The Reporting Person disclaims beneficial ownership of these securities [held by the Shaw Family Trust], and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Industry Context

This filing represents a routine insider transaction related to executive compensation, common across publicly traded companies, and does not reflect broader industry trends or competitive shifts.

Related Party Transactions

• The Shaw Family Trust holds 2,000,000 shares indirectly, with the Reporting Person's spouse as trustee and children as beneficiaries. The Reporting Person disclaims beneficial ownership.

Stakeholder Impact

• Shareholders: The filing indicates a routine increase in insider ownership through RSU conversion, partially offset by tax-related sales, which is a standard part of executive compensation and generally has a neutral impact on existing shareholders.
• Employees: The RSU vesting demonstrates the company's executive compensation structure in action.

Next Steps

• Remaining Restricted Stock Units are scheduled to vest on March 7, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax obligations. Such events are standard for executive compensation and do not typically provide new information that would warrant a change in investment thesis. There are no operational or strategic updates that would significantly alter the company's valuation or outlook. Therefore, a 'hold' recommendation is appropriate as the filing does not present new catalysts for either significant upside or downside.

Keywords

Marimed Inc., MRMD, Timothy Shaw, Chief Operating Officer, Form 4, SEC Filing, Insider Trading, Restricted Stock Units, RSU Conversion, Stock Ownership, Executive Compensation, Share Disposition, Tax Withholding